Non-covalent Interaction With SUMO Enhances the Activity of Human Cytomegalovirus Protein IE1.
Immediate early proteins (IE)
NMR spectroscopy
SUMO
cytomegalovirus
host-virus interaction
transactivation
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
02
2021
accepted:
20
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Viruses interact with the host cellular pathways to optimize cellular conditions for replication. The Human Cytomegalovirus (HCMV) Immediate-Early protein 1 (IE1) is the first viral protein to express during infection. It is a multifunctional and conditionally essential protein for HCMV infection. SUMO signaling regulates several cellular pathways that are also targets of IE1. Consequently, IE1 exploits SUMO signaling to regulate these pathways. The covalent interaction of IE1 and SUMO (IE1-SUMOylation) is well studied. However, the non-covalent interactions between SUMO and IE1 are unknown. We report two SUMO-Interacting Motifs (SIMs) in IE1, one at the end of the core domain and another in the C-terminal domain. NMR titrations showed that IE1-SIMs bind to SUMO1 but not SUMO2. Two critical functions of IE1 are inhibition of SUMOylation of Promyelocytic leukemia protein (PML) and transactivation of viral promoters. Although the non-covalent interaction of IE1 and SUMO is not involved in the inhibition of PML SUMOylation, it contributes to the transactivation activity. The transactivation activity of IE1 was previously correlated to its ability to inhibit PML SUMOylation. Our results suggest that transactivation and inhibition of PML SUMOylation are independent activities of IE1.
Identifiants
pubmed: 34055792
doi: 10.3389/fcell.2021.662522
pmc: PMC8155523
doi:
Types de publication
Journal Article
Langues
eng
Pagination
662522Informations de copyright
Copyright © 2021 Tripathi, Chatterjee and Das.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Virol. 2006 Aug;80(16):8006-18
pubmed: 16873257
PLoS Pathog. 2015 Mar 26;11(3):e1004785
pubmed: 25812002
Mol Cell. 2009 Mar 13;33(5):570-80
pubmed: 19285941
J Virol. 2010 Aug;84(16):8111-23
pubmed: 20519406
Bioinformatics. 2015 Nov 1;31(21):3483-91
pubmed: 26142185
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
Cell Commun Signal. 2017 Jul 14;15(1):27
pubmed: 28705221
J Virol. 2008 Nov;82(21):10444-54
pubmed: 18701593
J Virol. 2017 Jan 31;91(4):
pubmed: 27903803
Trends Biotechnol. 2006 Jan;24(1):22-7
pubmed: 16216358
J Virol. 2005 Sep;79(17):11467-75
pubmed: 16103197
Mol Cell. 2006 Nov 3;24(3):331-9
pubmed: 17081985
J Virol. 1997 Jun;71(6):4638-48
pubmed: 9151857
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17234-9
pubmed: 15572445
Methods Mol Biol. 2009;497:167-86
pubmed: 19107417
J Virol. 1995 Dec;69(12):7759-67
pubmed: 7494286
J Virol. 2017 Apr 28;91(10):
pubmed: 28250117
J Gen Virol. 2018 Mar;99(3):369-378
pubmed: 29458530
J Virol. 1984 Jan;49(1):190-9
pubmed: 6317889
Antiviral Res. 2018 Feb;150:79-92
pubmed: 29037975
J Virol. 2014 Jan;88(2):1228-48
pubmed: 24227840
J Virol. 2009 Dec;83(24):12854-70
pubmed: 19812155
J Virol. 2001 Nov;75(22):10683-95
pubmed: 11602710
Viruses. 2020 Jan 16;12(1):
pubmed: 31963209
Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14373-8
pubmed: 15388847
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13126-31
pubmed: 23878222
J Virol. 2002 Apr;76(8):3731-8
pubmed: 11907212
Curr Issues Mol Biol. 2020;35:1-16
pubmed: 31422930
J Virol. 1996 Nov;70(11):7867-77
pubmed: 8892909
Elife. 2016 Jan 26;5:
pubmed: 26812545
J Virol. 1997 Oct;71(10):7227-39
pubmed: 9311796
Mol Cell. 2009 Apr 24;34(2):145-54
pubmed: 19394292
Mol Cell. 2008 Aug 8;31(3):371-82
pubmed: 18691969
J Mol Biol. 2020 Mar 27;432(7):1952-1977
pubmed: 32001251
J Virol. 2009 Dec;83(23):12388-98
pubmed: 19776115
Arch Virol. 2005 Sep;150(9):1763-82
pubmed: 15931461
J Virol. 1995 Jan;69(1):182-8
pubmed: 7983709
J Virol. 2002 Mar;76(6):2990-6
pubmed: 11861864
J Immunol. 2005 Nov 15;175(10):6812-9
pubmed: 16272338
J Biol Chem. 2019 Oct 4;294(40):14546-14561
pubmed: 31371453
PLoS Pathog. 2011 Apr;7(4):e1002016
pubmed: 21533215
J Virol. 2018 Aug 16;92(17):
pubmed: 29950413
J Virol. 1989 Mar;63(3):1435-40
pubmed: 2536844
J Virol. 2004 Jun;78(12):6527-42
pubmed: 15163746
Virol Sin. 2014 Dec;29(6):343-52
pubmed: 25501994
Nucleic Acids Res. 2012 Sep;40(16):7831-43
pubmed: 22705796